<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774809</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10828</org_study_id>
    <nct_id>NCT04774809</nct_id>
  </id_info>
  <brief_title>Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-Controlled, Phase II/Ⅲ Seamless Adaptive Clinical Trail to Evaluate the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of SHR0302 ointment in adult&#xD;
      patients with Vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II/Ⅲ seamless adaptive clinical trial to evaluate the efficacy and&#xD;
      safety of SHR0302 ointment in adult patients with non-segmental vitiligo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">August 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2</measure>
    <time_frame>24 weeks</time_frame>
    <description>Phase 2: Percentage of change in face and neck vitiligo area scoring index (F-VASI) compared with baseline at week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3</measure>
    <time_frame>24 weeks</time_frame>
    <description>Phase 3: Percentage of subjects whose face and neck vitiligo area scoring index improved by at least 75% (F-VASI75) compared with the baseline at week 24.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>SHR0302 Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 SHR0302 Ointment BID Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 SHR0302 Ointment BID High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: vehicle Vehicle BID Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose SHR0302 Ointment BID</intervention_name>
    <description>Low Dose SHR0302 Ointment BID</description>
    <arm_group_label>SHR0302 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose SHR0302 Ointment BID</intervention_name>
    <description>High Dose SHR0302 Ointment BID</description>
    <arm_group_label>SHR0302 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: Vehicle</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Comparator: Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily signed an informed consent form.&#xD;
&#xD;
          2. Ages at ≥18 and ≤ 65 years&#xD;
&#xD;
          3. Clinical diagnosis of non-segmental vitiligo.&#xD;
&#xD;
          4. All women and men who are likely to give birth must be willing to use at least one&#xD;
             efficient method of contraception from the signing of the informed consent form to 1&#xD;
             month after the last dose of IP.&#xD;
&#xD;
          5. Subjects who agree to discontinue all vitiligo-related treatments and camouflage&#xD;
             cosmetics with therapeutic effect between screening visit and the last follow-up&#xD;
             visit.&#xD;
&#xD;
          6. Subjects who are willing and able to comply with the scheduled visits and treatment&#xD;
             plan, laboratory testing and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who were diagnosed with segmental vitiligo, mixed vitiligo or unclassified&#xD;
             vitiligo.&#xD;
&#xD;
          2. Subjects with historical or current evidence of clinically significant disease or lab&#xD;
             test abnormalities or with disease that require the administration of prohibited drugs&#xD;
             in this study.&#xD;
&#xD;
          3. Subjects with a malignant tumor or a history of malignant tumor (except for fully&#xD;
             treated or resected skin non-metastatic basal cell carcinoma or squamous cell&#xD;
             carcinoma).&#xD;
&#xD;
          4. Pregnant or lactating female subjects;&#xD;
&#xD;
          5. Subjects who have previously received JAK inhibitors therapy, systemic or oral&#xD;
&#xD;
          6. Subjects who had used any biologics within12 weeks before the baseline or 5 half-lives&#xD;
             (whichever is longer).&#xD;
&#xD;
          7. Subjects who participated in other interventional clinical studies within 4 weeks&#xD;
             before the baseline visit, or who were still within 5 half-lives of the last dose of&#xD;
             the intervention clinical study drug at baseline.&#xD;
&#xD;
          8. Subjects who received a live or live-attenuated vaccination within 8 weeks before the&#xD;
             baseline visit.&#xD;
&#xD;
          9. Any other condition that causes the subject to be unfit for the study as per&#xD;
             discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Doris Zhu</last_name>
    <phone>15021603639</phone>
    <email>doris.zhu@reistonebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imran Ghiasuddin</last_name>
    <email>imran.ghiasuddin@reistonebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao JI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bin YANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan No.1 Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liuqing Chen</last_name>
      <email>13163399822@163.com</email>
    </contact>
    <investigator>
      <last_name>Liuqing Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunyin LI</last_name>
      <email>xjyyllwyh@163.com</email>
    </contact>
    <investigator>
      <last_name>Chunyin LI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangfeng Ding</last_name>
      <email>dingyangfeng@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yangfeng DING</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China School of Medicine</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin XIONG</last_name>
      <email>huaxilunli@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin XIONG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Litao A Zhang</last_name>
      <email>zhanglitao@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Litao ZHANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hangzhou Third Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai'e XU</last_name>
    </contact>
    <investigator>
      <last_name>Ai'e Ai'e</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao CHENG Hao CHENG</last_name>
      <email>zryllwyh@163.com</email>
    </contact>
    <investigator>
      <last_name>Hao CHENG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo No.2 Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinyan WANG Jinyan WANG</last_name>
      <email>rypamy@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinyan WANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jillin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Shi</last_name>
    </contact>
    <investigator>
      <last_name>Shanshan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun. Yai- Sen Memorial Hospital, Sun. Yai- Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing Guo</last_name>
    </contact>
    <investigator>
      <last_name>Qing GUO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Tao</last_name>
    </contact>
    <investigator>
      <last_name>Xiaohua TAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoxin P Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Yan LU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated To Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Chao</last_name>
      <email>drquanchao@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinhua XU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

